Human kidney tissues from patients with CKD express higher levels of METTL3; therefore, modification of the METTL3-mediated RNA methylation pathway could be a therapeutic target for the development and progression of kidney fibrosis. This evidence concerns the gene METTL3 and chronic kidney disease.